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environmental temporal circumstances surrounding the appearance of symptoms. With knowledge of the pathophysiologic mechanisms responsible for the clinical manifestations and an awareness of the risks for causing neurotoxic effects characteristic of certain chemicals, the neurologist brings a high index of suspicion to the differentiation of neurotoxic syndromes from other neurologic disorders of nonneurotoxic origin. In addition, the neurologist can determine worker fitness and assess risks of increased susceptibility in a given individual to known neurotoxicant exposures at otherwise safe levels (1) .
Specific clinical manifestations result from damage to selected cellular elements such as the neurons, glial cells, myelin sheaths, or blood vessels. Central nervous system structures are affected more by some chemicals, while the peripheral nervous system is the main target of others. Certain substances affect both central and peripheral nervous tissues. Neurologic impairments result from direct or indirect effects of a neurotoxicant. Neurotoxic effects occur when enzymatic protective mechanisms fail to detoxify the neurotoxicant and eliminate it as a nontoxic byproduct. Neurotoxicants alter function of the nervous system by changing the lipid content of cell membranes and damaging capillary endothelium, by affecting their ability to transport ions and nutrients, by interfering with mitochondrial oxidative processes, and by disturbing neurotransmitter activity. Depending upon the neurotoxicant, the nature and duration of exposure, and the vulnerability of the cellular targets, neurotoxic effects may be reversible or irreversible.
The patient is commonly unaware of any relationship between any symptoms and his exposure to particular chemicals. He simply knows that he feels unwell. Nonspecific systemic effects of neurotoxicants include vegetative symptoms such as nausea, dizziness, and headache. The patient may not recognize changes in his behavior before they are brought to his attention by family members or co-workers. Behavioral symptoms such as poor attention, memory troubles, and delirium are obvious when they interfere with daily tasks. Central nervous system symptoms usually precede the symptoms of peripheral neuropathy. Early recognition of one case of neurotoxic disease should raise concern about possible exposure of other persons within the same environment. Continued exposure may produce effects in the others in the group, as well as allowing for further damage to those already affected.
Clinical Approach to Diagnosis of Neurotoxic Disease
Lists of chemical substances, the industries in which they might be found, and their most common neurotoxic effects can be found in reference books (2, 3) . Environmental and occupational health information can be accessed from various electronic data systems such as EPA ON-LINE Library System; National Library of Medicine ( (4) . With this information, and by learning from the patient about his work and environmental background, the clinician can be alerted to the risks of neurotoxic exposure. More likely, the patient's complaints will trigger a search for neurotoxic effects (Table 1 )(5).
Neurologic Eamination
The neurologist follows a systematic approach to differentiate nonneurotoxic disease from neurotoxic disease. A general medical examination is followed by a detailed neurologic examination to establish the clinical-anatomical basis for any symptom described. Tests (12) . Subgrouping and unit analysis have been used to define relationships between exposure and neurophysiologic impairments as measured by electrophysiologic techniques (13, 14) .
Electrophysiologic tests are not applied uniformly. Differences in techniques and instrumentation and variables among study populations often account for inconsistency among the data collected and its interpretation (15) . The clinical neurologist must take this into account when evaluating the results obtained in individual cases and especially in groups of individuals. Published and generally accepted electrophysiologic procedures should be used to measure and report motor and sensory latencies and amplitudes of evoked nerve action potentials and to calculate conduction velocities (9, 16, 17 WVhile it is reasonable to depend upon the findings and opinions of an expert consultant in area and personal sampling, the neurologist involved in evaluating the patient for neurotoxic disease must be critical when reviewing reports of environmental monitoring and exposure sampling. Important factors to consider include sensitivity and specificity of sampling and analytic methods; type of samples (area or personal sampling); timing of samples; use of personal protective equipment and safety practices; consideration of all possible routes of exposure; and exposure to combinations of neurotoxicants (19) . As in epidemiologic research, the use of a particular biologic measurement as a marker of exposure or effect also requires validation in the clinical setting. Validity of a marker is defined in terms of its sensitivity and specificity. The (20, 21) .
Formulating a Diagnosis
Findings on general and neurologic examination that represent a variance from conventionally accepted clinical norms, as defined in textbooks and reference works that consider neurologic functions, are abnormalities. Sets of physiologic, anatomic, and behavioral concepts and principles accumulated from experience and derived from a database of previously published reports known to the examiner serve as a frame of reference for evaluating these abnormalities in formulating a diagnosis and in offering a causal explanation. A clinical diagnosis in a patient is arrived at by an intellectual process that integrates all available information in a systematic manner. This process should be the same whether used in the day-to-day practice of clinical medicine or in the special circumstances of evaluating self-referred individuals suspected of neurotoxic disease and involved in litigation.
Boston University Environmental Neurology Assessment (BUENA)
Diagnosing effects of neurotoxicants rests on the ability of the clinician to recognize the risk that certain environmental agents can cause adverse biologic responses in nervous tissue at critical levels of exposure and absorption. A constellation of neurologic effects ranging from subclinical or barely perceptible sensory deficits to gross behavioral abnormalities may characterize a population at risk (22) . A high index of suspicion is needed to recognize individual cases or outbreaks of neurotoxic illness in communities, especially in the absence of a dramatic accident or an obvious hazardous waste spill. In communities where potential hazards, such as chemical waste disposal sites exist or where manufacturing processes are located near water supply sources, occurrences of exposure can be presumed (23) .
Appropriate and sensitive procedures must be applied for detecting and characterizing disturbances in neurologic and behavioral functions, as well as documenting the nature and extent of any hazardous conditions. The U.S. Environmental Protection Agency (U.S. EPA) (24) uses a multi-tiered laboratory approach for testing neurotoxicity in animals, in which a variety of measurements are integrated into a health or safety index. Such multiple parameter screening procedures parallel the process of human assessment that incorporates various findings of clinical neurologic examinations, electrophysiologic measurements of peripheral and CNS functions, and observations and test scores of standardized neuropsychologic studies and leads to a clinical diagnosis.
In an effort to standardize a procedure for clinical assessment of neurotoxic disease in individuals as well as in groups, we have developed the Boston University This approach formalizes techniques as they are used in the everyday practice of medicine, where the goal is to assess impairments of an individual within his environment. In this context, differing from the traditional epidemiologic study, the clinician takes the position that even a small probability of serious illness must not be dismissed (25 Average abnormalities in the neurophysiologic studies did not appear to be related to the cumulative exposure on a group basis. However, on an individual basis, 
